Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better...
Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026 SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer...
Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026
13 oral presentations included, reaffirming the clinical value of AI-based medical image analysis Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification SEOUL, South Korea, March...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading...
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer...
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision...
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a...
Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
Studies reveal how the Lunit SCOPE ® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading...
Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence
The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI...
Volpara Earns ACR® Learning Network Vendor Partner Designation
LYNNWOOD, Wash., Oct. 16, 2025 /PRNewswire/ -- Volpara Health has qualified for the American College of Radiology® (ACR®) Learning Network Vendor Partner designation. Volpara Health partnered with one of the latest graduates of the ACR ImPower...